Journal article
Rivaroxaban in Peripheral Artery Disease After Revascularization: Worst Events and Net Outcomes in VOYAGER PAD.
Abstract
BACKGROUND: VOYAGER PAD (Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities) demonstrated that antiplatelet therapy with rivaroxaban 2.5 mg twice daily compared with placebo reduced the first event in a composite end point in patients with peripheral artery disease after …
Authors
Hogan S; Szarek M; Debus ES; Nehler M; Anand SS; Patel MR; Pap AF; Deng H; Hodge S; Haskell LP
Journal
Journal of the American Heart Association, Vol. 14, No. 21,
Publisher
Wolters Kluwer
Publication Date
November 4, 2025
DOI
10.1161/jaha.124.039752
ISSN
2047-9980